84 related articles for article (PubMed ID: 16489086)
1. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
2. Native MAG-1 antibody almost destroys human breast cancer xenografts.
North WG; Pang RH; Gao G; Memoli VA; Cole BF
Breast Cancer Res Treat; 2011 Jun; 127(3):631-7. PubMed ID: 20625819
[TBL] [Abstract][Full Text] [Related]
3. Plasma HGF concentration in patients with brain tumors.
Siedlecki Z; Grzyb S; Rość D; Śniegocki M
AIMS Neurosci; 2020; 7(2):107-119. PubMed ID: 32607415
[TBL] [Abstract][Full Text] [Related]
4. Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.
Cecchi F; Rex K; Schmidt J; Vocke CD; Lee YH; Burkett S; Baker D; Damore MA; Coxon A; Burgess TL; Bottaro DP
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672409
[TBL] [Abstract][Full Text] [Related]
5. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents.
Grundy M; Narendran A
Front Pediatr; 2022; 10():910268. PubMed ID: 36034555
[TBL] [Abstract][Full Text] [Related]
6. Circular RNA LPAR3 sponges microRNA-198 to facilitate esophageal cancer migration, invasion, and metastasis.
Shi Y; Fang N; Li Y; Guo Z; Jiang W; He Y; Ma Z; Chen Y
Cancer Sci; 2020 Aug; 111(8):2824-2836. PubMed ID: 32495982
[TBL] [Abstract][Full Text] [Related]
7. The multiple paths towards MET receptor addiction in cancer.
Duplaquet L; Kherrouche Z; Baldacci S; Jamme P; Cortot AB; Copin MC; Tulasne D
Oncogene; 2018 Jun; 37(24):3200-3215. PubMed ID: 29551767
[TBL] [Abstract][Full Text] [Related]
8. The long noncoding RNA XIAP-AS1 promotes XIAP transcription by XIAP-AS1 interacting with Sp1 in gastric cancer cells.
Cai J; Wang D; Bai ZG; Yin J; Zhang J; Zhang ZT
PLoS One; 2017; 12(8):e0182433. PubMed ID: 28792527
[TBL] [Abstract][Full Text] [Related]
9. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
Zhang Y; Jain RK; Zhu M
Biomedicines; 2015 Mar; 3(1):149-181. PubMed ID: 28536405
[TBL] [Abstract][Full Text] [Related]
10. HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation.
Spina A; De Pasquale V; Cerulo G; Cocchiaro P; Della Morte R; Avallone L; Pavone LM
Biomedicines; 2015 Jan; 3(1):71-88. PubMed ID: 28536400
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
[TBL] [Abstract][Full Text] [Related]
12. MET overexpression and gene amplification in NSCLC: a clinical perspective.
Landi L; Minuti G; D'Incecco A; Salvini J; Cappuzzo F
Lung Cancer (Auckl); 2013; 4():15-25. PubMed ID: 28210131
[TBL] [Abstract][Full Text] [Related]
13. In vitro models of cancer stem cells and clinical applications.
S Franco S; Szczesna K; Iliou MS; Al-Qahtani M; Mobasheri A; Kobolák J; Dinnyés A
BMC Cancer; 2016 Sep; 16(Suppl 2):738. PubMed ID: 27766946
[TBL] [Abstract][Full Text] [Related]
14. Investigational new drugs for brain cancer.
Staedtke V; Bai RY; Laterra J
Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
[TBL] [Abstract][Full Text] [Related]
15. Tumor talk: understanding the conversation between the tumor and its microenvironment.
Whipple CA
Cancer Cell Microenviron; 2015 Apr; 2(2):e773. PubMed ID: 26023680
[TBL] [Abstract][Full Text] [Related]
16. Cancer associated fibroblasts in hematological malignancies.
Raffaghello L; Vacca A; Pistoia V; Ribatti D
Oncotarget; 2015 Feb; 6(5):2589-603. PubMed ID: 25474039
[TBL] [Abstract][Full Text] [Related]
17. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.
Lee JK; Joo KM; Lee J; Yoon Y; Nam DH
Onco Targets Ther; 2014; 7():1933-44. PubMed ID: 25364264
[TBL] [Abstract][Full Text] [Related]
18. The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer.
Cecchi F; Rabe DC; Bottaro DP
Curr Signal Transduct Ther; 2011; 6(2):146-151. PubMed ID: 25197268
[TBL] [Abstract][Full Text] [Related]
19. Targeting the oncogenic Met receptor by antibodies and gene therapy.
Vigna E; Comoglio PM
Oncogene; 2015 Apr; 34(15):1883-9. PubMed ID: 24882574
[TBL] [Abstract][Full Text] [Related]
20. Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling.
Woodard CL; Goodwin CR; Wan J; Xia S; Newman R; Hu J; Zhang J; Hayward SD; Qian J; Laterra J; Zhu H
PLoS One; 2013; 8(9):e72671. PubMed ID: 24023761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
